Current indications for phlebotropic therapy and its duration
Phlebotropic therapy is an important component of the pathogenetic treatment of chronic venous insufficiency (CVI) of the lower extremities. Venoactive drugs, which have proven their effectiveness and safety in a variety of studies, are widely represented in international and Russian clinical guidel...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
Remedium Group LTD
2021-06-01
|
| Series: | Амбулаторная хирургия |
| Subjects: | |
| Online Access: | https://www.a-surgeon.ru/jour/article/view/224 |
| _version_ | 1797883963456356352 |
|---|---|
| author | V. Yu. Bogachev B. V. Boldin P. Yu. Turkin O. V. Dzhenina A. Yu. Samenkov |
| author_facet | V. Yu. Bogachev B. V. Boldin P. Yu. Turkin O. V. Dzhenina A. Yu. Samenkov |
| author_sort | V. Yu. Bogachev |
| collection | DOAJ |
| description | Phlebotropic therapy is an important component of the pathogenetic treatment of chronic venous insufficiency (CVI) of the lower extremities. Venoactive drugs, which have proven their effectiveness and safety in a variety of studies, are widely represented in international and Russian clinical guidelines and standards. However, there is no consensus on the regulation of phlebotropic therapy and, above all, its duration in different clinical classes of CVI. In addition, there are no clear indications on the methods of treatment efficacy monitoring, which can be used in real clinical practice. The presented systematized review of the literature data on micronized purified flavonoid fraction not only reveals the possibilities of phlebotropic therapy of different clinical classes and forms of CVI, but also suggests effective regulations for the use of this drug in specific situations. The data concerning the efficacy of phlebotropic therapy in real clinical practice at the initial stages of CVI (C0s-C1s), in the treatment of C2s (varicose superficial veins with venospecific symptoms), C3 (chronic venous edema), C4 (trophic skin disorders), as well as in stages C5-C6 and C6r (venous trophic ulcers) are presented in details. In addition, the results of studies on the use of micronized purified flavonoid fraction in phlebosclerosing treatment are presented. The duration of phlebotropic therapy is in direct relation to the severity of the disease and the response to the ongoing treatment. The important role is played not only by personalization of treatment according to specific symptoms and syndromes, but also, if possible, by objective control of their dynamics. |
| first_indexed | 2024-04-10T04:00:03Z |
| format | Article |
| id | doaj.art-0072465de5174139b06e57008c675026 |
| institution | Directory Open Access Journal |
| issn | 2712-8741 2782-2591 |
| language | Russian |
| last_indexed | 2024-04-10T04:00:03Z |
| publishDate | 2021-06-01 |
| publisher | Remedium Group LTD |
| record_format | Article |
| series | Амбулаторная хирургия |
| spelling | doaj.art-0072465de5174139b06e57008c6750262023-03-13T07:10:18ZrusRemedium Group LTDАмбулаторная хирургия2712-87412782-25912021-06-01181132310.21518/1995-1477-2021-18-1-13-23202Current indications for phlebotropic therapy and its durationV. Yu. Bogachev0B. V. Boldin1P. Yu. Turkin2O. V. Dzhenina3A. Yu. Samenkov4Российский национальный исследовательский медицинский университет имени Н.И. Пирогова; Первый флебологический центрРоссийский национальный исследовательский медицинский университет имени Н.И. ПироговаРоссийский национальный исследовательский медицинский университет имени Н.И. ПироговаПервый флебологический центрРоссийский национальный исследовательский медицинский университет имени Н.И. ПироговаPhlebotropic therapy is an important component of the pathogenetic treatment of chronic venous insufficiency (CVI) of the lower extremities. Venoactive drugs, which have proven their effectiveness and safety in a variety of studies, are widely represented in international and Russian clinical guidelines and standards. However, there is no consensus on the regulation of phlebotropic therapy and, above all, its duration in different clinical classes of CVI. In addition, there are no clear indications on the methods of treatment efficacy monitoring, which can be used in real clinical practice. The presented systematized review of the literature data on micronized purified flavonoid fraction not only reveals the possibilities of phlebotropic therapy of different clinical classes and forms of CVI, but also suggests effective regulations for the use of this drug in specific situations. The data concerning the efficacy of phlebotropic therapy in real clinical practice at the initial stages of CVI (C0s-C1s), in the treatment of C2s (varicose superficial veins with venospecific symptoms), C3 (chronic venous edema), C4 (trophic skin disorders), as well as in stages C5-C6 and C6r (venous trophic ulcers) are presented in details. In addition, the results of studies on the use of micronized purified flavonoid fraction in phlebosclerosing treatment are presented. The duration of phlebotropic therapy is in direct relation to the severity of the disease and the response to the ongoing treatment. The important role is played not only by personalization of treatment according to specific symptoms and syndromes, but also, if possible, by objective control of their dynamics.https://www.a-surgeon.ru/jour/article/view/224веноактивные препаратымикронизированная очищенная флавоноидная фракцияэффективностьварикозное расширениехронический венозный отектрофические нарушения коживенозные трофические язвы |
| spellingShingle | V. Yu. Bogachev B. V. Boldin P. Yu. Turkin O. V. Dzhenina A. Yu. Samenkov Current indications for phlebotropic therapy and its duration Амбулаторная хирургия веноактивные препараты микронизированная очищенная флавоноидная фракция эффективность варикозное расширение хронический венозный отек трофические нарушения кожи венозные трофические язвы |
| title | Current indications for phlebotropic therapy and its duration |
| title_full | Current indications for phlebotropic therapy and its duration |
| title_fullStr | Current indications for phlebotropic therapy and its duration |
| title_full_unstemmed | Current indications for phlebotropic therapy and its duration |
| title_short | Current indications for phlebotropic therapy and its duration |
| title_sort | current indications for phlebotropic therapy and its duration |
| topic | веноактивные препараты микронизированная очищенная флавоноидная фракция эффективность варикозное расширение хронический венозный отек трофические нарушения кожи венозные трофические язвы |
| url | https://www.a-surgeon.ru/jour/article/view/224 |
| work_keys_str_mv | AT vyubogachev currentindicationsforphlebotropictherapyanditsduration AT bvboldin currentindicationsforphlebotropictherapyanditsduration AT pyuturkin currentindicationsforphlebotropictherapyanditsduration AT ovdzhenina currentindicationsforphlebotropictherapyanditsduration AT ayusamenkov currentindicationsforphlebotropictherapyanditsduration |